As Biotechnology companies, Pacific Biosciences of California Inc. (NASDAQ:PACB) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) are our subject to contrast. And more specifically their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California Inc.	84.03M	12.61	92.53M	-0.73	0.00
Paratek Pharmaceuticals Inc.	5.17M	44.25	111.46M	-3.64	0.00

In table 1 we can see Pacific Biosciences of California Inc. and Paratek Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Pacific Biosciences of California Inc. (NASDAQ:PACB) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California Inc.	-110.12%	-91.1%	-59.6%
Paratek Pharmaceuticals Inc.	-2,155.90%	-132.5%	-44.6%

Volatility & Risk

A 2.58 beta indicates that Pacific Biosciences of California Inc. is 158.00% more volatile compared to Standard and Poor’s 500. Paratek Pharmaceuticals Inc. on the other hand, has 1.03 beta which makes it 3.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The current Quick Ratio of Pacific Biosciences of California Inc. is 5.7 while its Current Ratio is 6.6. Meanwhile, Paratek Pharmaceuticals Inc. has a Current Ratio of 11.4 while its Quick Ratio is 11.4. Paratek Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Pacific Biosciences of California Inc.

Analyst Recommendations

Ratings and Recommendations for Pacific Biosciences of California Inc. and Paratek Pharmaceuticals Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Pacific Biosciences of California Inc.	0	2	0	2.00
Paratek Pharmaceuticals Inc.	0	1	1	2.50

The downside potential is -8.19% for Pacific Biosciences of California Inc. with average target price of $6.5. Competitively the average target price of Paratek Pharmaceuticals Inc. is $13.5, which is potential 90.41% upside. The data provided earlier shows that Paratek Pharmaceuticals Inc. appears more favorable than Pacific Biosciences of California Inc., based on analyst opinion.

Insider & Institutional Ownership

Institutional investors owned 78.7% of Pacific Biosciences of California Inc. shares and 82.6% of Paratek Pharmaceuticals Inc. shares. Pacific Biosciences of California Inc.’s share owned by insiders are 4.33%. Comparatively, Paratek Pharmaceuticals Inc. has 2.9% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Pacific Biosciences of California Inc.	-3.84%	-2.59%	60%	137.22%	171.48%	184.85%
Paratek Pharmaceuticals Inc.	-9.11%	-11.05%	-31.2%	-36.88%	-61.02%	-61.56%

For the past year Pacific Biosciences of California Inc. has 184.85% stronger performance while Paratek Pharmaceuticals Inc. has -61.56% weaker performance.

Summary

Pacific Biosciences of California Inc. beats Paratek Pharmaceuticals Inc. on 7 of the 12 factors.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.